<DOC>
	<DOCNO>NCT01237223</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ( blood pressure lower effect ) safety SPA100 ( Fixed-dose Combination Aliskiren Amlodipine ) patient essential hypertension ( mean sit diastolic blood pressure [ msDBP ] ≥ 95 mmHg &lt; 110 mmHg mean sit systolic blood pressure [ msSBP ] ≥ 140 mmHg ) . This study conduct support registration fixed-dose combination aliskiren amlodipine treatment hypertension Japan .</brief_summary>
	<brief_title>Efficacy Safety SPA100 ( Fixed-dose Combination Aliskiren/Amlodipine ) Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patients essential hypertension ( msDBP ≥ 95 mmHg &lt; 110 mmHg msSBP ≥140 mmHg ) Outpatients Severe hypertension ( msDBP ≥110 mmHg and/or msSBP ≥ 180 mmHg ) History allergy hypersensitivity renin inhibitor , calcium channel blocker History evidence secondary hypertension Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Aliskiren</keyword>
	<keyword>Amlodipine</keyword>
	<keyword>Essential hypertension</keyword>
</DOC>